论文部分内容阅读
目的研究分析美托洛尔联合螺内酯治疗扩张型心肌病合并心力衰竭的临床效果。方法选取2013年5月—2015年5月本院收治的扩张型心肌病合并心力衰竭患者82例,随机分为对照组、观察组各41例。对照组采用常规治疗,给予观察组美托洛尔6.25 mg/次,2次/d,螺内酯40 mg/次,2次/d。两组均6周为1个疗程。对比两组临床治疗有效率和治疗前后心功能指标变化,计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组临床治疗有效率为97.56%,显著高于对照组的78.05%,对比差异有统计学意义(P<0.05)。观察组治疗后心率(heart rate,HR)显著低于对照组[(70.6±5.1)、(80.4±3.8)次/min],对比差异有统计学意义(P<0.05)。观察组治疗后左室缩短分数(left ventricular fractional shortening,LVFS)、左室射血分数(left ventricular ejection fraction,LVEF)、每分钟心排血量(cardiac output,CO)和每搏输出量(stroke volume,SV)均显著优于对照组[(30.4±4.8)%、(23.1±5.4)%、(43.2±7.3)%、(35.8±8.5)%、(4.4±1.8)、(3.8±0.3)L/min、(64.4±6.2)、(45.3±7.1)ml],对比差异均有统计学意义(均P<0.05)。结论美托洛尔联合螺内酯治疗扩张型心肌病合并心力衰竭效果显著,能够有效提高临床治疗有效率,改善心功能,缓解患者病情,值得推广。
Objective To study the clinical effect of metoprolol combined with spironolactone in the treatment of dilated cardiomyopathy with heart failure. Methods 82 patients with dilated cardiomyopathy and heart failure admitted to our hospital from May 2013 to May 2015 were randomly divided into control group and observation group of 41 cases. Patients in the control group were treated with metoprolol 6.25 mg twice daily and spironolactone 40 mg twice daily. Both groups were 6 weeks for a course of treatment. Comparison of two groups of clinical treatment efficiency and changes in cardiac function before and after treatment, measurement data using t test, count data usingχ2 test, P <0.05 for the difference was statistically significant. Results The effective rate of clinical treatment in observation group was 97.56%, which was significantly higher than that in control group (78.05%). The difference was statistically significant (P <0.05). The heart rate (HR) in the observation group was significantly lower than that in the control group [(70.6 ± 5.1), (80.4 ± 3.8) times / min], the difference was statistically significant (P <0.05). The left ventricular fractional shortening (LVFS), left ventricular ejection fraction (LVEF), cardiac output (CO) and stroke volume volume and SV were significantly better than those in the control group [(30.4 ± 4.8)%, (23.1 ± 5.4)%, (43.2 ± 7.3)%, (35.8 ± 8.5)%, (4.4 ± 1.8) and (3.8 ± 0.3) L / min, (64.4 ± 6.2) and (45.3 ± 7.1) ml, respectively. The differences were statistically significant (all P <0.05). Conclusion Metoprolol combined with spironolactone in the treatment of patients with dilated cardiomyopathy complicated with heart failure has a significant effect, which can effectively improve the efficiency of clinical treatment, improve cardiac function and relieve the patient’s condition, which is worth promoting.